Despite having advantages over conventional whole breast irradiation, hypofractionated WBI is used by only a third of patients who would benefit.
The FDA has approved olaparib, to be marketed under the name Lynparza, for the treatment of advanced ovarian cancer related to defective BRCA genes.
The highest rates of cervical cancer occur in women aged 65 to 69, according to new estimates. This suggests that screening guidelines may need to be reconsidered.
The sexual behaviors and beliefs about HPV infection were unchanged among a group of teens and young women who were vaccinated against the virus, research shows.
New evidence reveals that there may be a benefit to continuing cervical cancer screening beyond age 65 years.
Women whose cervical cancer screening ceased between ages 50 and 64 years were 6 times more likely than women who were screened to have cervical cancer from ages 65 to 83 years.
Diagnosis and treatment of high-grade cervical dysplasia substantially increases the risk of cervical or vaginal cancer at or after age 60 years, a study finds.
A simple blood test using plasma thermogram could serve as an effective new indicator for detecting cervical cancer, including assessment of the cancer’s stage.
Researchers discovered 13 gene mutations of significance in cervical cancer, including 8 mutations not previously linked to cervical cancer and 2 mutations novel to any type of cancer.
The surgical outcomes of single port pelvic surgeries (SiPPS) for a variety of gynecologic oncology indications are similar to those of traditional laparoscopic techniques.